BioArctic revenue and financials
kr 300.20Change from previous close: −0.33%Absolute change: −kr 1.00
In the fiscal year ended December 2025, BioArctic reported revenue of kr 2B (+676.80% year over year). Net income was kr 1.02B, a net margin of 51.1%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +676.80%
- 2025 vs 2024
- Net margin
- 51.1%
- 2024: -68.8%
Financial data
Amounts in millions of SEK; per-share values in SEK; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total revenue | 248 | 438 | 184 | 133 | 392 |
| Cost of revenue | 21.7 | 19.5 | 15.1 | 12.2 | 20.5 |
| Gross profit | 226 | 418 | 169 | 121 | 372 |
| Selling, general and administrative | 58.4 | 52.4 | 49.4 | 50.3 | 49.1 |
| Research and development | 170 | 151 | 84.9 | 95.5 | 112 |
| Operating income | -6.5 | 211 | 33.2 | -28.8 | 179 |
| EBIT | 7.4 | 225 | 44.0 | -18.3 | 188 |
| EBITDA | 7.4 | 225 | 44.0 | -18.3 | 188 |
| Interest expense | 1.0 | 0.5 | 4.9 | 2.7 | 16.1 |
| Pre-tax income | 6.4 | 224 | 39.1 | -20.9 | 171 |
| Income tax | 17.5 | 11.7 | 47.9 | 65.9 | 74.9 |
| Net income | -11.2 | 212 | -8.8 | -86.9 | 96.6 |
| Net income to common shareholders | -11.2 | 212 | -8.8 | -86.9 | 96.6 |
| Basic EPS | -0.13 | 2.40 | -0.10 | -0.98 | 1.09 |
| Diluted EPS | -0.13 | 2.39 | -0.10 | -0.98 | 1.09 |
| Average shares (basic) | 88.7 | 88.6 | 88.6 | 88.6 | 88.5 |
| Average shares (diluted) | 88.7 | 88.9 | 88.6 | 88.6 | 88.5 |